Which selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) is most likely to cause drowsiness or help with sleep?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Which SSRI or SNRI Causes the Most Drowsiness or Helps Sleep?

Among SSRIs and SNRIs, paroxetine (Paxil) is the most sedating option, with somnolence reported in 18-21.6% of patients compared to 7.8% with placebo, making it the best choice when sedation is desired. 1

Evidence-Based Ranking by Sedating Properties

Most Sedating: Paroxetine (SSRI)

  • Paroxetine causes somnolence in 18-21.6% of patients at therapeutic doses (20-60 mg/day), significantly higher than placebo (7.8%). 1
  • The sedating effect is dose-related, with higher rates at 40-60 mg/day compared to 20 mg/day. 1
  • Paroxetine has weak anticholinergic activity that contributes to its sedating profile, distinguishing it from other SSRIs. 2, 3
  • Research demonstrates paroxetine suppresses REM sleep and increases sleep fragmentation more than other SSRIs like citalopram at equivalent doses, indicating stronger serotonergic effects that promote sedation. 4
  • The American Academy of Family Physicians specifically describes paroxetine as "less activating but more anticholinergic than other SSRIs." 5

Moderately Sedating Options

  • SNRIs (duloxetine, venlafaxine) can cause somnolence as a common adverse effect, though specific incidence rates are lower than paroxetine. 6
  • Duloxetine and venlafaxine both list somnolence among their adverse effects, but they also paradoxically cause insomnia in some patients. 7, 6

Least Sedating (Activating): Fluoxetine and Sertraline

  • Fluoxetine is the most activating SSRI and should be avoided when sedation is desired. 5
  • Sertraline is moderately activating and causes insomnia in 16-25% of patients. 5
  • These medications are typically dosed in the morning to minimize sleep disturbance. 5

Clinical Algorithm for Selection

When sedation/sleep promotion is the goal:

  1. First-line: Paroxetine 10-20 mg at bedtime

    • Start with 10 mg and increase to 20 mg after 1 week if needed. 5
    • Maximum dose 40 mg/day, though sedation is evident at lower doses. 1
    • Expect somnolence in approximately 1 in 5 patients. 1
  2. Alternative if paroxetine contraindicated: Duloxetine (SNRI)

    • Start 30 mg once daily for 1 week, then increase to 60 mg. 7
    • Nausea is more common than with paroxetine, but sedation can occur. 7
  3. Avoid entirely: Fluoxetine and sertraline

    • These cause insomnia and activation rather than sedation. 5

Important Caveats and Pitfalls

Discontinuation Syndrome Risk

  • Paroxetine has the highest risk of discontinuation syndrome among SSRIs due to its short half-life (21 hours). 2, 8
  • When stopping paroxetine, taper slowly over several weeks to avoid withdrawal symptoms including dizziness, nausea, and sensory disturbances. 5
  • Fluoxetine has the lowest discontinuation risk due to its long half-life. 5

Anticholinergic Effects

  • Paroxetine's anticholinergic properties cause dry mouth (10.8-20.6%), constipation, and blurred vision more than other SSRIs. 1
  • Avoid paroxetine in elderly patients due to increased anticholinergic burden and fall risk. 5
  • Consider citalopram or escitalopram instead in older adults if an SSRI is needed. 5

Sexual Dysfunction

  • Paroxetine causes the highest rate of sexual dysfunction among SSRIs, with decreased libido in 6-15% of males and ejaculatory disturbance in 13-28%. 1
  • This may limit long-term adherence despite beneficial sedating effects. 1

Weight Gain

  • Paroxetine has a higher propensity for weight gain compared to other SSRIs with long-term use. 8

Drug Interactions

  • Paroxetine is both a substrate and inhibitor of CYP2D6, leading to potential drug interactions. 2
  • Monitor for serotonin syndrome when combining with other serotonergic agents. 6, 5

Cardiac Considerations

  • Unlike tricyclic antidepressants, paroxetine does not cause clinically significant cardiac conduction abnormalities at therapeutic doses. 3
  • However, all SSRIs carry a black box warning for suicidality in patients under age 25. 6, 5

Alternative Consideration: Mirtazapine (Not an SSRI/SNRI)

While not an SSRI or SNRI, mirtazapine (7.5-30 mg at bedtime) causes significant sedation and is specifically used to promote sleep, with initial sedation being one of its most common side effects. 9, 10 If the primary goal is sleep promotion rather than specifically requiring an SSRI/SNRI, mirtazapine may be superior to paroxetine for this indication. 9

References

Research

Paroxetine: a review.

CNS drug reviews, 2001

Research

Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2004

Guideline

Activating Effects of SSRIs

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Paroxetine: current status in psychiatry.

Expert review of neurotherapeutics, 2007

Guideline

Mirtazapine for Mitigating SSRI-Induced Sexual Dysfunction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.